Figure 3.

Donor NK CD107a degranulation toward activated T cells was predictive for risk of aGVHD, chronic GVHD, relapse, and overall survival. The Gray's test was applied for comparisons of cumulative incidences of acute GVHD, chronic GVHD, and relapse. Death, without aGVHD, was defined as the competing event for aGVHD, while relapse-free mortality was the competing event for relapse. Cumulative incidence estimates of grade I–IV aGVHD (A), gradeII–IV aGVHD (B), grade III–IV aGVHD (C), chronic GVHD (D), and relapse (E) or Kaplan–Meier survival estimates for overall survival (F) for patients in “CD107a^low” and “CD107a^high” groups, separated according to the optimal cutoff of 20.5% for donor NK CD107a degranulation toward activated T cells.